Clinical Trial Update: Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 3]

View source ↗

Summary

A phase 3 trial compares olaparib alone or the combination of cediranib and olaparib versus standard chemotherapy for women with platinum-sensitive ovarian, fal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Cediranib (Cediranib)
• Olaparib (Olaparib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2021-03-12